Areas of Research

Epigenetic regulation of myeloma

Multiple myeloma is in many ways a disease driven by inappropriate gene expression. It is characterised by the aberrant activation of gene regulatory elements known as enhancers, stimulating the upregulation of key oncogenes. Blocking this behaviour is therefore a promising strategy for myeloma treatment, and many therapeutic strategies directly or indirectly target gene regulatory pathways.

The lab studies the epigenetic regulation of gene expression, focused on the way these processes are dysregulated in multiple myeloma. We have a particular interest in understanding the role of oncogenic enhancer activity in driving myeloma-specific transcriptional profiles, and identifying the factors responsible for this behaviour. A major goal of the lab is to identify potential therapeutic targets that could be developed as novel therapies for multiple myeloma.

We use a variety of high-throughput genomics techniques to study the chromatin landscape, including ChIP-seq, ATAC-seq and RNA-seq. We have optimised TOPmentation, a small cell-number technique that allows us to characterise the chromatin profile of myeloma patient samples. In addition, we use the 3C technology Micro-Capture-C to map the physical association of enhancers and promoters. By combining these techniques with genetic and pharmacological manipulation of myeloma cell lines, we are able to explore mechanistically enhancer function and regulation.

Mechanisms of myeloma drug resistance

Relapse is very common in myeloma after initial treatment. Patients typically enter remission following treatment, but invariably relapse, often with resistance to one or more of these drugs. There is therefore a pressing need to understand the mechanisms that drive this resistance to find ways to counteract it. We are working to identify and understand epigenetic mechanisms that drive drug resistance via changes in gene expression, which therefore may be reversed to resensitise cells to therapy.

Our team

Jinglin Zhou (he/him)

Jinglin Zhou (he/him)
PhD student

Jason Taslim (he/him)

Jason Taslim (he/him)
Research assistant

Sophie Ball (she/her)

Sophie Ball (she/her)
PhD student

Funders

Research Publications

Citation

BibTex format

@article{Smith:2025:10.1182/blood.2024028019,
author = {Smith, AL and Denny, N and Chahrour, C and Sharp, K and Arachi, M and Dopico-Fernandez, AM and Elliott, N and Harman, JR and Jackson, T and Geng, H and Smith, O and Bond, J and Roberts, I and Stam, RW and Crump, NT and Davies, JOJ and Roy, A and Milne, TA},
doi = {10.1182/blood.2024028019},
journal = {BLOOD},
pages = {2073--2087},
title = {Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients},
url = {http://dx.doi.org/10.1182/blood.2024028019},
volume = {146},
year = {2025}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AU - Smith,AL
AU - Denny,N
AU - Chahrour,C
AU - Sharp,K
AU - Arachi,M
AU - Dopico-Fernandez,AM
AU - Elliott,N
AU - Harman,JR
AU - Jackson,T
AU - Geng,H
AU - Smith,O
AU - Bond,J
AU - Roberts,I
AU - Stam,RW
AU - Crump,NT
AU - Davies,JOJ
AU - Roy,A
AU - Milne,TA
DO - 10.1182/blood.2024028019
EP - 2087
PY - 2025///
SN - 0006-4971
SP - 2073
TI - Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients
T2 - BLOOD
UR - http://dx.doi.org/10.1182/blood.2024028019
VL - 146
ER -